Navigating the complexities of market entry for medicinal products, medical devices, in-vitro diagnostics (IVDs), and advanced therapy medicinal products (ATMPs) requires a solid understanding of the European healthcare landscape. As healthcare expenditures continue to rise, the challenge of securing favorable pricing and reimbursement has intensified across the region. Successful integration into these markets depends on a well-prepared communication strategy that clearly demonstrates a product’s clinical and economic value to relevant authorities and payers.